Literature DB >> 34333491

Prolapse Surgery: What Kind of Antibiotic Prophylaxis Is Necessary?

Ester Illiano1, Francesco Trama1, Felice Crocetto2, Gianluigi Califano2, Achille Aveta2, Gloria Motta3, Antonio Luigi Pastore4, Stefano Brancorsini5, Consuelo Fabi5, Elisabetta Costantini1.   

Abstract

INTRODUCTION: The aim of this study was to assess whether antibiotic prophylaxis or therapy is sufficient for laparoscopic or vaginal prolapse surgery with mesh.
METHODS: This is a single-center prospective study. The study was divided into 3 groups. Protocol A: metronidazole (15 mg/kg) and piperacillin-tazobactam (2 g) 1 h before surgery and, for postoperative treatment, gentamycin (160 mg) 1 h before surgery in a single dose. Metronidazole and piperacillin-tazobactam were administered until hospital discharge. Protocol B: gentamycin and piperacillin-tazobactam in the same manner as group A. Protocol C: clindamycin (600 mg) and gentamicin (160 mg) 1 h before surgery in a single dose.
RESULTS: We included 87 consecutive patients who underwent prolapse surgery involving mesh prostheses: 57 by the laparoscopic approach and 30 by the vaginal route. Of these, 30 patients were included in protocol A, 30 in protocol B, and 27 in protocol C. There were no statistically significant differences among the 3 protocols regarding any postoperative complications, except for urinary tract infections that were more in the vaginal approach than in the laparoscopic route, in protocol A (p = 0.002).
CONCLUSIONS: One-shot prophylaxis can be successfully used in prolapse surgery regardless of the surgical approach.
© 2021 S. Karger AG, Basel.

Entities:  

Keywords:  Antibiotic prophylaxis; Complication surgery; Infection mesh; Laparoscopic sacrocolpopexy; Prolapse surgery

Mesh:

Substances:

Year:  2021        PMID: 34333491     DOI: 10.1159/000517788

Source DB:  PubMed          Journal:  Urol Int        ISSN: 0042-1138            Impact factor:   2.089


  1 in total

1.  Comparison of first versus second line sacrocolpopexies in terms of morbidity and mid-term efficacy.

Authors:  Marine Lallemant; A T M Grob; M Puyraveau; M A G Perik; A H H Alhafidh; M Cosson; R Ramanah
Journal:  Sci Rep       Date:  2022-09-29       Impact factor: 4.996

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.